Physician profile
Sameer Bisarya
NPI 1255379426
$1,797.93
in general payments reported to CMS, 2019-2025
19 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.66 · 2022: $117 · 2023: $293 · 2024: $555 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.69 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $401.64 | 2021-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $306.42 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $167.45 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $144.50 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $111.22 | 2024-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.62 | 2024 | Jardiance |
| Travere Therapeutics, INC. | $100.01 | 2023-2025 | |
| Glaxosmithkline, LLC. | $65.99 | 2021-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $64.47 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.25 | 2024-2025 | Jynarque |
| Novo Nordisk INC | $51.17 | 2024-2025 | Rivfloza |
| Amgen INC. | $48.55 | 2023-2024 | Tavneos, Parsabiv, Aranesp |
| Horizon Therapeutics Plc | $41.94 | 2022-2023 | Krystexxa |
| Sobi, INC | $37.07 | 2025 | |
| Vifor Pharma, INC. | $22.21 | 2024 | Veltassa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.12 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $19.56 | 2022 | |
| Scpharmaceuticals INC. | $17.53 | 2025 | |
| Daiichi Sankyo INC. | $16.21 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Bisarya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.